Impact of Triple Combination CFTR Therapy on Sinus Disease.

Status unconfirmed

Conditions studied: Cystic Fibrosis

In brief

The study's main goal is to observe how effective elexacaftor-tezacaftor-ivacaftor is for improving the symptoms and signs of CF-related sinus disease.

Key facts

Study ID

NCT04056702

Run by

Jennifer Taylor-Cousar

People needed

31

Starts

2019-09-05

Expected to finish

2022-07-01

Last updated by the study team

2021-03-11

Who can join

Age: 18 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects from 18 to 89 years old.
• Subjects with cystic fibrosis and comorbid chronic sinus disease (historic diagnosis based on physician assessment of signs and symptoms and medical record).
• Subjects who clinically elect to initiate elexacaftor-tezacaftor-ivacaftor therapy and/or that are ineligible for CFTR modulator therapy based on their genotype, but have class I/II mutations based on sweat chloride > 90 mmol/L.

You may not qualify if…

• Subjects under the age of 18 or over the age of 89.
• Subjects who do not elect to initiate elexacaftor-tezacaftor-ivacaftor for clinical reasons.
• Subjects who had sinus surgery within the last 6 months or will have sinus surgery during the study period.
• Subjects who have had a recent pulmonary exacerbation or viral infection within two weeks of initial visit.

Where it is running

• National Jewish Health — Denver, Colorado, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.